Trials / Completed
CompletedNCT02891590
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Zhejiang DTRM Biopharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The Primary Objective is to evaluate the safety and tolerability of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma. The Secondary Objective is to evaluate the pharmacokinetics of multiple dose oral administration of DTRMWXHS-12 capsule in patients with B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DTRMWXHS-12 |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2019-02-01
- Completion
- 2019-02-01
- First posted
- 2016-09-07
- Last updated
- 2020-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02891590. Inclusion in this directory is not an endorsement.